PL1883411T3 - Oligonukleotyd oraz kompozycja zawierająca oligonukleotyd do stosowania w leczeniu nowotworu komórek B - Google Patents

Oligonukleotyd oraz kompozycja zawierająca oligonukleotyd do stosowania w leczeniu nowotworu komórek B

Info

Publication number
PL1883411T3
PL1883411T3 PL06705637T PL06705637T PL1883411T3 PL 1883411 T3 PL1883411 T3 PL 1883411T3 PL 06705637 T PL06705637 T PL 06705637T PL 06705637 T PL06705637 T PL 06705637T PL 1883411 T3 PL1883411 T3 PL 1883411T3
Authority
PL
Poland
Prior art keywords
oligonucleotide
compositions
treating
same
cell neoplasm
Prior art date
Application number
PL06705637T
Other languages
English (en)
Polish (pl)
Inventor
Li-Ying Wang
Yong-Li Yu
Mu-Sheng Bao
Original Assignee
Changchun Huapu Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changchun Huapu Biotechnology Co Ltd filed Critical Changchun Huapu Biotechnology Co Ltd
Publication of PL1883411T3 publication Critical patent/PL1883411T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
PL06705637T 2005-05-17 2006-02-13 Oligonukleotyd oraz kompozycja zawierająca oligonukleotyd do stosowania w leczeniu nowotworu komórek B PL1883411T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2005100695764A CN1865275B (zh) 2005-05-17 2005-05-17 对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸
PCT/CN2006/000216 WO2006122464A1 (en) 2005-05-17 2006-02-13 An oligonucleotide or its functional homologue, a composition comprising the same and a method for treating b cell neoplasm
EP06705637.4A EP1883411B1 (de) 2005-05-17 2006-02-13 Oligonukleotid und dieses enthaltende Zusammensetzungen zur Behandlung eines B-Zellen-Neoplasma

Publications (1)

Publication Number Publication Date
PL1883411T3 true PL1883411T3 (pl) 2014-01-31

Family

ID=37424439

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06705637T PL1883411T3 (pl) 2005-05-17 2006-02-13 Oligonukleotyd oraz kompozycja zawierająca oligonukleotyd do stosowania w leczeniu nowotworu komórek B
PL06705636T PL1883647T3 (pl) 2005-05-17 2006-02-13 Oligonukleotyd i zawierające go mieszaniny do leczenia nowotworów komórek B

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06705636T PL1883647T3 (pl) 2005-05-17 2006-02-13 Oligonukleotyd i zawierające go mieszaniny do leczenia nowotworów komórek B

Country Status (22)

Country Link
US (3) US20090202567A1 (de)
EP (2) EP1883411B1 (de)
JP (2) JP4837033B2 (de)
KR (2) KR101346716B1 (de)
CN (1) CN1865275B (de)
AU (2) AU2006246897B2 (de)
BR (2) BRPI0609885A2 (de)
CA (2) CA2609062C (de)
CY (1) CY1114844T1 (de)
DK (2) DK1883647T3 (de)
ES (2) ES2433129T3 (de)
HK (2) HK1112745A1 (de)
IL (2) IL187249A (de)
MX (2) MX2007014146A (de)
NZ (1) NZ563582A (de)
PL (2) PL1883411T3 (de)
PT (2) PT1883647E (de)
RU (2) RU2409672C2 (de)
SI (2) SI1883647T1 (de)
UA (2) UA94231C2 (de)
WO (2) WO2006122463A1 (de)
ZA (2) ZA200710311B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524899A (ja) * 2008-06-18 2011-09-08 インデックス・ファーマシューティカルズ・アクチエボラーグ がんの併用療法
CN101643496B (zh) * 2008-08-07 2015-09-09 长春华普生物技术有限公司 一种具有免疫抑制功能的寡核苷酸
EP2350282A1 (de) * 2008-11-04 2011-08-03 Index Pharmaceuticals AB Verstärkte expression spezifischer antigene
CA2859698C (en) * 2010-12-21 2021-03-02 Index Pharmaceuticals Ab Methods for identifying biologically active oligonucleotides capable of modulating the immune system
WO2012084991A1 (en) * 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
CN106893724B (zh) * 2015-12-17 2023-05-02 苏州派动生物技术有限公司 具有抗原增效作用和肿瘤治疗作用的寡核苷酸
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200158A (et) 1999-09-25 2003-06-16 University Of Iowa Research Foundation Immunostimulatoorsed nukleiinhapped
CN1981868A (zh) * 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
EP1296714B1 (de) 2000-06-22 2009-08-26 University Of Iowa Research Foundation Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
US20040009156A1 (en) 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
AU2002356962C1 (en) * 2001-12-12 2008-05-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
DE10258677A1 (de) 2002-12-13 2004-06-24 Elez, Vera, Dr. Kombinations-antisense-Oligonukleotid-Krebstherapie
CN100439386C (zh) * 2003-03-05 2008-12-03 长春华普生物技术有限公司 增强蛋白类疫苗免疫效果的含CpG单链脱氧寡核苷酸
CN100486987C (zh) * 2003-03-05 2009-05-13 长春华普生物技术有限公司 抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸
ATE532792T1 (de) 2003-07-25 2011-11-15 Changchun Huapu Biotechnology Co Ltd Künstliches cpg einzelstrang oligodeoxynukleotid und dessen antivirale anwendungen
JP4513879B2 (ja) 2008-03-05 2010-07-28 ソニー株式会社 像ぶれ補正装置、レンズ鏡筒装置及びカメラ装置

Also Published As

Publication number Publication date
UA91057C2 (ru) 2010-06-25
EP1883647B1 (de) 2013-10-23
UA94231C2 (ru) 2011-04-26
AU2006246898B2 (en) 2011-08-18
PT1883647E (pt) 2014-01-20
HK1112745A1 (en) 2008-09-12
KR20080007655A (ko) 2008-01-22
BRPI0609885A2 (pt) 2010-05-04
BRPI0609882A2 (pt) 2010-05-04
ZA200710312B (en) 2009-08-26
KR20080011426A (ko) 2008-02-04
JP4837033B2 (ja) 2011-12-14
EP1883411B1 (de) 2013-08-14
ZA200710311B (en) 2009-08-26
US20090202567A1 (en) 2009-08-13
SI1883647T1 (sl) 2014-02-28
WO2006122463A1 (en) 2006-11-23
KR101294131B1 (ko) 2013-08-07
KR101346716B1 (ko) 2014-01-02
MX2007014145A (es) 2008-03-07
DK1883647T3 (da) 2014-01-27
HK1113318A1 (en) 2008-10-03
EP1883647A4 (de) 2010-10-06
IL187249A0 (en) 2008-02-09
CA2609062C (en) 2013-11-19
RU2007146706A (ru) 2009-06-27
ES2433129T3 (es) 2013-12-09
AU2006246897A1 (en) 2006-11-23
US8133874B2 (en) 2012-03-13
EP1883647A1 (de) 2008-02-06
IL187281A (en) 2012-04-30
CY1114844T1 (el) 2016-12-14
DK1883411T3 (da) 2013-11-18
SI1883411T1 (sl) 2014-01-31
ES2442462T3 (es) 2014-02-11
JP2008539768A (ja) 2008-11-20
CA2609062A1 (en) 2006-11-23
JP4837034B2 (ja) 2011-12-14
CA2609067A1 (en) 2006-11-23
RU2413519C2 (ru) 2011-03-10
US20090162279A1 (en) 2009-06-25
MX2007014146A (es) 2008-03-07
CN1865275B (zh) 2011-06-15
AU2006246897B2 (en) 2012-04-12
RU2007146705A (ru) 2009-06-27
PL1883647T3 (pl) 2014-03-31
RU2409672C2 (ru) 2011-01-20
IL187281A0 (en) 2011-08-01
EP1883411A4 (de) 2010-10-06
PT1883411E (pt) 2013-11-11
US8450292B2 (en) 2013-05-28
US20120142761A1 (en) 2012-06-07
CN1865275A (zh) 2006-11-22
IL187249A (en) 2012-03-29
AU2006246898A1 (en) 2006-11-23
WO2006122464A1 (en) 2006-11-23
EP1883411A1 (de) 2008-02-06
NZ563582A (en) 2010-04-30
JP2008539767A (ja) 2008-11-20

Similar Documents

Publication Publication Date Title
EP2153838A4 (de) Anti-norovirus-wirkstoff und zusammensetzung damit
IL228770A0 (en) processes and intermediates
IL206127A0 (en) Azolylmethyloxiranes, use thereof and agents containing the same
EP1895838A4 (de) Zusammensetzungen und verfahren
PL2271725T3 (pl) Kompozycje zawierające 2,3,3,3-tetrafluoropropen i 1,1,1-trifluoropropen
GB0522287D0 (en) Method and compositions
TWI316258B (en) Adjustable delay cells and delay lines including the same
IL200905A0 (en) Compounds and compositions comprising the same for use in treating hepatitis c
IL211089A0 (en) Compositions and methods for cell killing
IL200846A0 (en) Oligomer-protease inhibitor conjugates, compositions comprising the same and uses thereof
IL186127A (en) Subcutaneous preparations for the treatment of depression and methods for their preparation
EP1935942A4 (de) Masterbatch und diesen enthaltende zusammensetzung
EP2182980A4 (de) Verfahren und zusammensetzungen für erhöhte alpha-iduronidase-aktivität im zns
GB2426974B (en) RDX composition and process
IL200847A0 (en) Oligomer-antihistamine inhibitor conjugates, compositions comprising the same and uses thereof
IL184834A0 (en) Compositions and methods for the manufacture thereof
ZA200800346B (en) Catalyst composition and process using same
GB0516254D0 (en) Improvements in devices
HK1112745A1 (en) Oligonucleotide and compositions comprising the same for treating b cell neoplasm
GB2441918B (en) Chemical compounds and liquid-crystal compositions comprising the compounds
EP1848438A4 (de) Diaminophenothiazin-zusammensetzungen und deren verwendung
EP1852499A4 (de) Neurotisationsförderndes agens
ZA200608935B (en) Methods and compositions for epilation
TWI346671B (en) Chemical composition and process
EP1781337A4 (de) Verfahren und zusammensetzungen zur zellaktivierung